Prestige Consumer Healthcare (NYSE:PBH) Rating Lowered to Strong Sell at Zacks Research

Key Points

• Prestige Consumer Healthcare has been downgraded from a "hold" rating to a "strong sell" rating by Zacks Research, indicating a significant negative shift in analyst sentiment.
• The company's stock has dropped 2.5%, currently trading around $65.06, with a consensus target price of $93.33 according to MarketBeat.com.
• Recently reported quarterly earnings missed expectations, with earnings per share (EPS) of $0.95 compared to the consensus estimate of $1.01, contributing to a decline in revenue of 6.6% year-over-year.

Zacks Research cut shares of Prestige Consumer Healthcare (NYSE:PBH - Free Report) from a hold rating to a strong sell rating in a research note published on Thursday, September 4th,Zacks.com reports.

PBH has been the subject of several other research reports. Wall Street Zen downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Canaccord Genuity Group reduced their price target on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Finally, Royal Bank Of Canada raised shares of Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $93.33.

Prestige Consumer Healthcare Trading Up 0.3%

Shares of PBH stock traded up $0.20 during trading hours on Thursday, hitting $65.24. 208,372 shares of the company were exchanged, compared to its average volume of 406,336. The firm has a market cap of $3.21 billion, a P/E ratio of 15.31, a P/E/G ratio of 2.09 and a beta of 0.46. Prestige Consumer Healthcare has a fifty-two week low of $62.95 and a fifty-two week high of $90.04. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. The company has a 50 day simple moving average of $71.16 and a two-hundred day simple moving average of $79.53.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing the consensus estimate of $1.01 by ($0.06). The company had revenue of $249.53 million for the quarter, compared to analyst estimates of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business's quarterly revenue was down 6.6% compared to the same quarter last year. During the same period last year, the business earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Equities analysts anticipate that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of hedge funds have recently made changes to their positions in PBH. Kayne Anderson Rudnick Investment Management LLC bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth $84,932,000. Norges Bank bought a new stake in shares of Prestige Consumer Healthcare during the second quarter valued at about $41,848,000. Invesco Ltd. increased its position in shares of Prestige Consumer Healthcare by 24.7% during the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock valued at $113,635,000 after buying an additional 261,537 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of Prestige Consumer Healthcare by 1,073.3% during the fourth quarter. BNP Paribas Financial Markets now owns 203,903 shares of the company's stock worth $15,923,000 after purchasing an additional 186,524 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Prestige Consumer Healthcare by 11,580.3% during the first quarter. GAMMA Investing LLC now owns 161,538 shares of the company's stock worth $13,887,000 after purchasing an additional 160,155 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.